Highest-materiality recent filing
Sunshine Biopharma Q1 revenue up 18% to $8.9M; net loss narrows
Revenue of $8.9 million in Q1 2025, up 18% from $7.5M in Q1 2024.
Sunshine Biopharma closes $2.46M registered direct offering of common stock and pre-funded warrants
Gross proceeds of approximately $2.46M from sale of 1,188,404 shares of common stock (or pre-funded warrants) at $2.07 per share.
Sunshine Biopharma FY2024 revenue $34.9M (+45% YoY); net loss widens to $5.1M
Revenue $34.9M in FY2024, up 45% from $24.1M in FY2023; gross profit $10.7M.
Sunshine Biopharma Q3 2024 revenues up 42% YoY; net loss widens 84% in quarter
Q3 2024 gross revenues $8.44M, up 42% from $5.96M in Q3 2023; YTD revenues $25.28M, up 54%.
Sunshine Biopharma gets Nasdaq bid-price extension to Aug 26, 2024
Received Nasdaq Hearings Panel exception until August 26, 2024 to regain minimum bid price compliance.
Nasdaq notifies Sunshine Biopharma of delisting due to warrant dilution
Nasdaq staff determined to delist SBFM under Rule 5101 citing public interest concerns over Series A warrant cashless exercise provision.
Sunshine Biopharma Q1 2024 revenue up 54% to $7.54M; net loss narrows to $1.28M
Q1 2024 revenue of $7,541,046, a 54% increase from $4,894,053 in Q1 2023.
Sunshine Biopharma dismisses auditor BF Borgers after SEC permanent ban
BF Borgers CPA, PC was dismissed as independent auditor after SEC settled charges and permanently banned the firm.
On January 13, 2025, Sunshine Biopharma Inc. (the “Company”) appointed Mr. Michel Roy as the Company’s Chief Commercial Officer.
Max materiality 0.85 · Median 0.50 · Most common event other_material